Squarepoint’s Ocata Therapeutics OCAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q1
– Sell
-11,500
Closed -$97K – 1662
2015
Q4
$97K Buy
+11,500
New +$77K 0.01% 1137

Squarepoint's OCAT Position: Q1 2016 in Review

Squarepoint sold out of Ocata Therapeutics (OCAT) in Q1 2016, closing a stake of 11,500 shares — an estimated $97K sold.

Squarepoint first reported a position in OCAT in Q4 2015 and held it in 1 quarter. The position peaked at $97K in Q4 2015. 1 fund tracked by Wall St. Rank holds OCAT as of Q1 2016.

  • Squarepoint reported no remaining Ocata Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Squarepoint sold 11,500 Ocata Therapeutics shares in Q1 2016, an estimated $97K.
  • Squarepoint first reported a position in Ocata Therapeutics in Q4 2015 and held it in 1 quarter.
  • Squarepoint's Ocata Therapeutics position peaked at $97K in Q4 2015.
  • 1 fund tracked by Wall St. Rank held Ocata Therapeutics as of Q1 2016.

Based on Squarepoint's 13F filing for Q1 2016, filed 16 May 2016.